ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Authorization Legislation Still On Congress Busy Agenda, Along With Risk Assessment, Appropriations

February 3, 1984

Cooney to Oversee University of Michigan Clinical Operations

February 7, 2013

New Research Projects Proposed For Immunology

September 30, 1977

In This Issue: Congressional Testimony On NIH, NCI Appropriations, FDA Reform

May 9, 1997

Pooled Analysis of 12 Seperate Yervoy Studies Shows Survival-Curve Plateau at 3 Years

October 25, 2013

NCI, MABCO Publish Clinical Trials Web Site

September 6, 1996